Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2008-02-22
2011-12-06
Keys, Rosalynd (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S171000, C514S456000, C514S459000, C514S616000, C514S619000, C514S622000, C552S623000, C552S624000, C552S626000, C552S220000, C549S405000, C549S407000, C564S153000, C564S156000, C564S157000, C564S158000
Reexamination Certificate
active
08071575
ABSTRACT:
Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion.
REFERENCES:
patent: 5641762 (1997-06-01), Pierce et al.
patent: 6218519 (2001-04-01), Kenten et al.
patent: 6326366 (2001-12-01), Potter et al.
patent: 6503896 (2003-01-01), Tanabe et al.
patent: 7196220 (2007-03-01), Pierce et al.
patent: 2004/0097500 (2004-05-01), Liao et al.
patent: 2004/0110793 (2004-06-01), Lloyd et al.
patent: 2004/0241173 (2004-12-01), Wilson et al.
patent: 2005/0143366 (2005-06-01), Pierce et al.
patent: 2007/0161710 (2007-07-01), Pierce et al.
patent: 2008/0221070 (2008-09-01), Pierce et al.
patent: 2000066613 (2000-11-01), None
patent: 2004043336 (2004-05-01), None
patent: 2004043693 (2004-05-01), None
patent: 2005065315 (2005-07-01), None
Silverman (The Organic Chemistry of Drug Design and Drug Action, 1992, pp. 15-20.
Pierce, et al.; International Search Report and Written Opinion issued on PCT Application No. PCT/US2008/054790, May 2008.
Pierce, et al.; International Search Report and Written Opinion issued on PCT Application No. PCT/US2008/056100, Jun. 2008.
U.S. Appl. No. 12/036,057 to Pierce, et al., for “Bone Targeting Compounds for Delivering Agents to the Bone for Interaction Therewith”, Feb. 2008.
U.S. Appl. No. 12/043,904 to Pierce, et al., for “Bone Targeting Compounds for Delivering Agents to the Bone for Interaction Therewith”, Mar. 2008.
International Patent Application No. PCT/US2008/054790 to Pierce, et al., for “Bone Targeting Compounds for Delivering Agents to the Bone for Interaction Therewith”, May 2008.
International Patent Application No. PCT/US08/56100 to Pierce, et al., for “Bone Targeting Compounds for Delivering Agents to the Bone for Interaction Therewith” , Jun. 2008.
Bilezikian JP; Osteonedrosis of the Jaw—Do Bisphosphonates Pose a Risk N Engl J Med, (2006); pp. 2278-2281; vol. 355.
Cranney A, Adachi JD; Benefit-risk assessment of raloxifene in postmenopausal osteoporosis; Drug Saf (2005); pp. 721-730; vol. 28(8).
Delmas PD, et al.; The Use of Biochemical Markers of Bone Turnover in Osteoporosis; Osteoporosis Int. (2000); pp. S2-17; suppl 6.
Garrett IR, Chen D, Gutierrez G, Rossini G, Zhao M, Escobedo A, Kim KB, Hu S, Crews CM, and Mundy GR; Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro; J Clin Invest, (2003), pp. 1771-1782, vol. 111(11).
Ishida H; Preventive effects of the plant isoflavones, daidzin and genistin, on bone loss in ovariectomized rats fed a calcium-deficient diet; Biol Pharm Bull. Jan. 1998:21; pp. 62-66; vol. (1).
Keenan MJ, Hegsted M, Jones KL, Delany JP, Kime JC, Melancon LE, Tulley RT, Hong KD. Comparison of bone density measurement techniques: DXA and Archimedes' principle; J Bone Miner Res (1997); pp. 1903-1907; vol. 12(11).
Marshall JK ; The gastrointestinal tolerability and safety of oral bisphosphonates; Expert Opin Drug Saf; (2002); pp. 71-78; vol. 1.
Mundy GR, Garrett R, Harris SE, Chan J, Chen D, Rossini G, Boyce B, Zhao M, and Gutierrez G; Stimulation of bone formation in vitro and in rodents by statins. Science (1999); pp. 1946-1949; vol. 286 (5446).
Pierce; Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro; Proceedings of the Society for Experimental Biology and Medicine [0037-9727] (1987) vol. 186 iss:1 pp. 96-102.
Riggs BL, and Parfitt AM; Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling, J. Bone and Mineral Res. (2005); p. 177-184; vol. 20(2).
Rossouw JE, et al.; Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002); pp. 321-333; vol. 288(3).
Seibel MJ.; Biochemical Markers of Bone Turnover: biochemistry and variability; Clin Biochem Rev. (2005); pp. 97-122; vol. 26(4).
Vahle JL, et al.; Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety; Toxicol Pathol (2002); pp. 312-321; vol. 30(3).
Pierce, Jr. William M.
Taylor K. Grant
Waite Leonard C.
Decker Mandy Wilson
Keys Rosalynd
Stites & Harbison PLLC
University of Louisville Research Foundation
LandOfFree
Methods and compounds for the targeted delivery of agents to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compounds for the targeted delivery of agents to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compounds for the targeted delivery of agents to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296559